Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | EGFR | P00533 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29506315 | 1.00 | MAPT (0.57) | MAPTNPC1RAB9ASMN1; SMN2LIMK1 | |
| SCHEMBL1521622 | 0.75 | MAPT (0.58) | MAPTNPC1RAB9ASMN1; SMN2LIMK1 | |
| SCHEMBL10440555 | 0.75 | PARP1 (0.55) | MAPTNPC1RAB9ASMN1; SMN2LIMK1 | |
| SCHEMBL6686925 | 0.70 | MAPT (0.66) | MAPTNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL29506285 | 0.70 | MAPT (0.66) | MAPTNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL31609494 | 0.69 | ALDH1A1 (0.50) | MAPTNPC1RAB9ASMN1; SMN2LIMK1 | |
| SCHEMBL4934675 | 0.69 | ALDH1A1 (0.50) | MAPTNPC1RAB9ASMN1; SMN2LIMK1 | |
| SCHEMBL903237 | 0.69 | MAPT (0.65) | MAPTNPC1RAB9ASMN1; SMN2TP53 | |
| Biphenyl SCHEMBL29177942 | 0.69 | TDO2 (0.50) | MAPTNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL29506282 | 0.69 | MAPT (0.65) | MAPTNPC1RAB9ASMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150141410-A1 | GPR17 Receptor Modulators | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2015-05-21 | — | — | US | claimed |
| US-20240351866-A1 | PROCESS FOR THE PRODUCTION OF HYDROGEN THROUGH ELECTRIFICATION OF WATER GAS SHIFT REACTION | TOTALENERGIES ONETECH (FR) | 2024-10-24 | — | — | US | disclosed |
| EP-4399178-A1 | PROCESS FOR THE PRODUCTION OF HYDROGEN THROUGH ELECTRIFICATION OF WATER GAS SHIFT REACTION | TotalEnergies OneTech (FR) | 2024-07-17 | — | — | EP | disclosed |
| US-20230272401-A1 | COMPOSITIONS FOR FLCN GENE MODULATION AND METHODS THEREOF | Genetic Intelligence, Inc | 2023-08-31 | — | — | US | disclosed |
| US-20230128889-A1 | REL/RELA/SPOT SMALL MOLECULES MODULATORS AND SCREENING METHODS | Université Libre de Bruxelles (BE) | 2023-04-27 | — | — | US | disclosed |
| WO-2023036857-A1 | PROCESS FOR THE PRODUCTION OF HYDROGEN THROUGH ELECTRIFICATION OF WATER GAS SHIFT REACTION | TOTALENERGIES ONETECH (FR) | 2023-03-16 | — | — | WO | disclosed |
| EP-4128250-A1 | REL/RELA/SPOT SMALL MOLECULES MODULATORS AND SCREENING METHODS | Université Libre de Bruxelles (BE) | 2023-02-08 | — | — | EP | disclosed |
| EP-3390403-B1 | PHARMACEUTICAL COMPOSITION COMPRISING INDOLE DERIVATIVES, PROCESS FOR PREPARATION AND USE THEREOF | VIVOLUX AB (SE) | 2022-06-29 | — | — | EP | disclosed |
| WO-2021197574-A1 | REL/RELA/SPOT SMALL MOLECULES MODULATORS AND SCREENING METHODS | Université Libre de Bruxelles (BE) | 2021-10-07 | — | — | WO | disclosed |
| US-10668056-B2 | Pharmaceutical composition comprising indole derivatives, process for preparation and use thereof | VIVOLUX AB (SE) | 2020-06-02 | — | — | US | disclosed |
| EP-2850068-B1 | N-(phenyl)-2-[[3-(phenyl)-1H-1,2,4-triazol-5-yl]thio]-acetamide derivatives and related compounds as G protein coupled receptor 17 (GPCR17) modulators for use in the treatment of neuro-degenerative diseases | UNIV DEGLI STUDI MILANO (IT) | 2019-05-29 | — | — | EP | disclosed |
| EP-3390403-A1 | PHARMACEUTICAL COMPOSITION COMPRISING INDOLE DERIVATIVES, PROCESS FOR PREPARATION AND USE THEREOF | Vivolux Ab (SE) | 2018-10-24 | — | — | EP | disclosed |
| US-20180280366-A1 | PHARMACEUTICAL COMPOSITION COMPRISING INDOLE DERIVATIVES, PROCESS FOR PREPARATION AND USE THEREOF | VIVOLUX AB (SE) | 2018-10-04 | — | — | US | disclosed |
| US-9879030-B2 | GPR17 receptor modulators | UNIVERSITA′ DEGLI STUDI DI MILANO (IT) | 2018-01-30 | — | — | US | disclosed |
| WO-2017102097-A1 | PHARMACEUTICAL COMPOSITION COMPRISING INDOLE DERIVATIVES, PROCESS FOR PREPARATION AND USE THEREOF | VIVOLUX AB (SE) | 2017-06-22 | — | — | WO | disclosed |
| US-20150141410-A1 | GPR17 Receptor Modulators | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2015-05-21 | — | — | US | disclosed |
| WO-2009035534-A2 | TREATMENT OF ISCHEMIC EYE DISEASE BY THE SYSTEMATIC PHARMACEUTICAL ACTIVATION OF HYPOXIA INDUCIBLE FACTOR (HIF) | THE CLEVELAND CLINIC FOUNDATION (US) | 2009-03-19 | — | — | WO | disclosed |
| EP-1131288-A1 | PYRROLIDINE DERIVATIVES-CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-09-12 | — | — | EP | disclosed |
| US-6166015-A | Pyrrolidine derivatives-CCR-3 receptor antagonists | SYNTEX (U.S.A.) INC. (US) | 2000-12-26 | — | — | US | disclosed |
| WO-2000031032-A1 | PYRROLIDINE DERIVATIVES-CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180280366-A1 | PHARMACEUTICAL COMPOSITION COMPRISING INDOLE DERIVATIVES, PROCESS FOR PREPARATION AND USE THEREOF | IDO1, IDO2, TPH1 | MAPT 2360/4885NPC1 1123/4885RAB9A 1977/4885 |
| US-20230272401-A1 | COMPOSITIONS FOR FLCN GENE MODULATION AND METHODS THEREOF | TARDBP, FUS, RBM17 | MAPT 343/4885NPC1 2076/4885RAB9A 2469/4885 |
| US-20150141410-A1 | GPR17 Receptor Modulators | GPR65, GPR27, GPR17 | MAPT 1710/4885NPC1 868/4885RAB9A 2491/4885 |
| US-10668056-B2 | Pharmaceutical composition comprising indole derivatives, process for preparation and use thereof | IDO1, IDO2, TPH1 | MAPT 2360/4885NPC1 1123/4885RAB9A 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.